GlassScriptPhysician profile
Joshua Lennon
NPI 1427369172
$11,315.61
in general payments reported to CMS, 2019-2025
21 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2021: $2,571 · 2022: $1,387 · 2023: $3,948 · 2024: $2,581 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,443 · Food and Beverage: $2,020 · Travel and Lodging: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,442.50 |
| Food and Beverage | $2,019.72 |
| Travel and Lodging | $1,404.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $6,416.33 | 2019-2024 | |
| Zoll Respicardia, INC. | $2,119.95 | 2022-2024 | Remede System |
| Inspire Medical Systems, INC. | $1,292.58 | 2022-2024 | Inspire |
| Harmony Biosciences LLC | $248.61 | 2022-2025 | Wakix |
| Resmed Corp | $240.00 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $187.17 | 2024-2025 | Lumryz |
| Emd Serono, INC. | $181.39 | 2019-2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $88.82 | 2019-2025 | |
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Sunovion Pharmaceuticals INC. | $75.57 | 2019 | |
| Amgen INC. | $74.53 | 2022 | |
| Abbvie INC. | $74.29 | 2023-2025 | |
| Insightec,INC | $67.31 | 2023 | Exablate |
| Takeda Pharmaceuticals U.S.A., INC. | $39.29 | 2025 | |
| Axsome Therapeutics, INC. | $31.69 | 2025 | Sunosi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $28.66 | 2019 | |
| Cycle Pharmaceuticals INC | $28.33 | 2025 | Tascenso Odt, Bafiertam |
| Nevro Corp. | $22.88 | 2021 | |
| Boston Scientific Corporation | $18.21 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Lennon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.